A strategic collaboration between Shear Kershman Laboratories, Texas A&M University College of Dentistry, and Innovative MedTech Inc. promises to revolutionize oral healthcare through the development of an innovative therapeutic platform targeting oral thrush treatment.
The newly signed Memorandum of Understanding (MOU) aims to advance medical and dental technologies by combining the organizations' unique strengths. Shear Kershman Labs brings healthcare innovation expertise, Texas A&M contributes academic research capabilities, and Innovative MedTech provides technological development prowess.
Central to the collaboration is BioViscid™, a groundbreaking long-lasting formulation designed to address oral candidiasis more effectively than existing treatments. Unlike current systemic medications like fluconazole or amphotericin B, BioViscid™ offers a targeted approach with sustained bio-adhesion across mucosal tissues.
Early trials demonstrate BioViscid™'s potential to deliver sustained medication release over 6-8 hours, maintaining effectiveness even during eating and drinking. The technology's unique amphipathic molecular structure and bio-adhesive encapsulation represent a significant advancement in drug delivery methods.
The significance of this innovation is underscored by oral thrush's substantial healthcare impact. Approximately 5-7% of Americans are affected, with higher risk among immunocompromised populations, including individuals with diabetes, HIV/AIDS, or cancer. The global market for oral candidiasis treatments is estimated at $4-6 billion, presenting considerable potential for transformative solutions.
Beyond developing BioViscid™, the partnership aims to advance medical education, conduct collaborative research, and create innovative healthcare solutions. The collaboration is expected to enhance academic programs, provide practical training opportunities, and potentially improve patient outcomes globally.
Dr. Blake Hawley from Shear Kershman Labs emphasized the formulation's potential, stating that BioViscid™ ensures sustained contact with affected areas, dramatically improving therapeutic outcomes. Dr. Lily T. Garcia, Dean of Texas A&M College of Dentistry, highlighted the partnership's transformative potential in aligning science, technology, and patient care.
The collaborative effort represents more than a technological development; it signifies a strategic approach to addressing complex healthcare challenges through interdisciplinary cooperation. By combining academic research, technological innovation, and clinical expertise, the partnership seeks to redefine oral healthcare treatment methodologies.
